Bank of America Securities Reiterates a Buy on Ascendis Pharma (ASND)

Ascendis Pharma A/S (NASDAQ:ASND) is one of the Best Performing Long Term Stocks According to Analysts. On September 15, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Ascendis Pharma A/S (NASDAQ:ASND) with a price target of $230.

The firm named the company as one of its top picks for 2025. This comes after the company’s Yorvipath global launch in hypoparathyroidism showed strong initial results with further acceleration as payor coverage expands.

The analyst noted that the company’s strong execution is reflected in its impressive 54.5% revenue growth over the last twelve months, maintaining a robust gross margin of 84.88%. Moreover, Ahmad also believes that Yorvipath is well-positioned to capture market share as the only marketed product in its category, with competing pipeline products reportedly several years behind in development. The bank currently models $3.15 billion in peak sales for Yorvipath in HPT, which it calculates represents $147 per share in value.

Ascendis Pharma A/S (NASDAQ:ASND) is a Denmark-based pharmaceutical company that develops treatments for growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes.

While we acknowledge the potential of ASND as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.